Literature DB >> 25477584

Infusion-related reaction following daptomycin two-minute rapid intravenous administration.

Celeste R Caulder1, Aaron Sloan1, Ahmed Yasir2, P Brandon Bookstaver1.   

Abstract

BACKGROUND: Erythroderma, or red man's syndrome, is a common infusion-related reaction following vancomycin administration. Erythroderma following daptomycin rapid infusion has not been documented.
OBJECTIVE: To report a case of erythroderma following daptomycin 2-minute intravenous (IV) injection. CASE REPORT: A review of published literature suggests that this is the first published case of a flushing (nonallergic) reaction resulting from a 2-minute IV injection of daptomycin that is not present with standard IV infusion. A 69-year-old woman following right knee reconstructive surgery presented with right knee joint swelling, purulent discharge, and fever. Subsequently, she was diagnosed with a presumed postsurgical infection and was initiated on vancomycin therapy. Following removal of the infected hardware, the patient was discharged and continued outpatient vancomycin therapy. The patient's renal function began to decline and therapy was discontinued. Daptomycin 6 mg/kg every 48 hours was initiated via 2-minute IV push. On the initial dose, approximately 2 hours post IV infusion, the patient began to notice redness and a warm sensation on her face, neck, and upper part of the chest. Diphenhydramine 25 mg provided limited immediate relief, but all symptoms subsided within 3 to 4 hours. The patient received her next dose 48 hours later over a 40-minute IV infusion with no adverse effects. Subsequent infusions continued at the same dose over 30 minutes for 4 weeks with no further adverse effects.
CONCLUSION: A 2-minute intravenous injection of daptomycin in this patient yielded a reaction that was not present on rechallenge with standard, extended infusion.

Entities:  

Keywords:  Staphylococcus aureus; daptomycin; erythroderma; rapid infusion; red man’s syndrome

Year:  2014        PMID: 25477584      PMCID: PMC4252235          DOI: 10.1310/hpj4907-644

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  6 in total

1.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 2.  Comparative safety of teicoplanin and vancomycin.

Authors:  A P Wilson
Journal:  Int J Antimicrob Agents       Date:  1998-05       Impact factor: 5.283

3.  The incidence of erythroderma: a survey among all dermatologists in The Netherlands.

Authors:  V Sigurdsson; P H Steegmans; W A van Vloten
Journal:  J Am Acad Dermatol       Date:  2001-11       Impact factor: 11.527

Review 4.  Daptomycin: the role of high-dose and combination therapy for Gram-positive infections.

Authors:  Ian M Gould; José M Miró; Michael J Rybak
Journal:  Int J Antimicrob Agents       Date:  2013-07-08       Impact factor: 5.283

5.  Red man syndrome.

Authors:  Soupramanien Sivagnanam; Dirk Deleu
Journal:  Crit Care       Date:  2002-12-23       Impact factor: 9.097

6.  Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection.

Authors:  Abhijit Chakraborty; Sandip Roy; Juergen Loeffler; Ricardo L Chaves
Journal:  J Antimicrob Chemother       Date:  2009-04-22       Impact factor: 5.790

  6 in total
  3 in total

1.  Intravenous Push Administration of Antibiotics: Literature and Considerations.

Authors:  Samantha Spencer; Heather Ipema; Patricia Hartke; Courtney Krueger; Ryan Rodriguez; Alan E Gross; Michael Gabay
Journal:  Hosp Pharm       Date:  2018-03-08

2.  High-Dose Daptomycin Is Well Tolerated via 2-Minute IV Push Administration.

Authors:  Christian M Gill; Rachel M Kenney; Charles T Makowski; Susan L Davis
Journal:  Hosp Pharm       Date:  2020-01-06

3.  tert-Butylphenylthiazoles with an oxadiazole linker: a novel orally bioavailable class of antibiotics exhibiting antibiofilm activity.

Authors:  Ahmed Kotb; Nader S Abutaleb; Mohamed Hagras; Ashraf Bayoumi; Mahmoud M Moustafa; Adel Ghiaty; Mohamed N Seleem; Abdelrahman S Mayhoub
Journal:  RSC Adv       Date:  2019-02-26       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.